SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Rantapää Dahlqvist Solbritt) srt2:(2005-2009)"

Sökning: WFRF:(Rantapää Dahlqvist Solbritt) > (2005-2009)

  • Resultat 1-10 av 73
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  •  
4.
  •  
5.
  • Alenius, Gerd-Marie, et al. (författare)
  • Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis?
  • 2009
  • Ingår i: Clinical and Experimental Rheumatology. - 0392-856X .- 1593-098X. ; 27:1, s. 120-123
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: To evaluate a possible systemic effect of joint inflammation in contrast to skin disease only, by measuring IL-6 and IL-2sRalpha. METHODS: Two hundred and nineteen patients (111 male / 108 female, age 50.4+/-14.5 yrs (mean+/-SD)) with psoriasis were clinically and laboratory examined. 134 patients had inflammatory joint manifestations defined as peripheral arthritis and/or axial disease, of whom 37 had measurable inflammation, defined as ESR >25 mm/h and/or CRP >15 mg/L. RESULTS: Interleukin-6 was significantly higher in patients with joint disease and measurable inflammation ((median, Q1-Q3) 4.07, 0.92-14.60), and in patients without measured inflammation (1.22, 0.70-3.46), compared to patients with skin disease only (0.70, 0.70-1.73, p<0.001 and p=0.002 respectively). The difference between the two groups of patients with inflammatory joint manifestations was significant (p=0.001). The levels of IL-6 correlated with the actual number of joints affected with arthritis (p<0.001; rs=0.248), ESR (p<0.001; rs=0.459), CRP (p<0.001; rs=0.314) and IL-2sRalpha (p=0.002; rs=0.210). The levels of IL-2sRalpha. did not differ between the 3 groups. CONCLUSION: In this study, IL-6 was significantly higher in patients with psoriasis and inflammatory joint disease with or without routine measurable inflammatory activity compared with patients having psoriasis of the skin. We found that patients with psoriasis and joint inflammation may have systemic effects that could be captured by serum measurements of IL-6. Soluble IL-2Ralpha was not a marker of inflammation in this study.
  •  
6.
  • Andersen, Grethe Neumann, et al. (författare)
  • Bronchoalveolar matrix metalloproteinase 9 relates to restrictive lung function impairment in systemic sclerosis.
  • 2007
  • Ingår i: Respiratory Medicine. - : Elsevier BV. - 0954-6111 .- 1532-3064. ; 101:10, s. 2199-2206
  • Tidskriftsartikel (refereegranskat)abstract
    • Systemic sclerosis (SSc) is frequently associated with interstitial lung disease (ILD) often leading to lung fibrosis. In this study we investigated whether matrix metalloproteinase 9 (MMP-9) and its natural inhibitor; the tissue inhibitor of matrix metalloproteinase 1 (TIMP-1), would be associated with remodelling in ILD in SSc. Levels of total MMP-9, pro-MMP-9 and TIMP-1 were measured in bronchoalveolar lavage (BAL) fluid from nine SSc patients with ILD, seven SSc patients without ILD and 16 age- and sex-matched healthy controls. Total MMP-9 and pro-MMP-9 levels were significantly elevated in SSc patients with ILD, compared to levels in SSc patients without ILD and healthy controls. In SSc patients with ILD calculated active MMP-9 levels were significantly higher than in SSc patients without ILD and tended to be higher than in healthy controls. TIMP-1 levels were elevated in both patient groups compared to healthy controls. Total-, pro- and active MMP-9 levels as well as pro-MMP-TIMP-1 and active MMP-9/TIMP-1 ratios were inversely associated with total lung capacity. The present study suggests that MMP-9 plays a pathophysiological role in the remodelling in ILD and lung fibrosis associated with SSc, and may represent a new therapeutic target in this condition.
  •  
7.
  •  
8.
  •  
9.
  • Askling, Johan, et al. (författare)
  • Anti-TNF therapy in RA and risk of malignant lymphomas Relative risks and time-trends in the Swedish Biologics Register
  • 2008
  • Ingår i: Annals of the Rheumatic Diseases. - : BMJ Publishing Group Ltd. - 0003-4967 .- 1468-2060. ; 68:5, s. 648-653
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Tumour necrosis factor (TNF) antagonists have proved effective as treatment against rheumatoid arthritis (RA), but the unresolved issue of whether the use of anti-TNF therapy increases the already elevated risk of lymphoma in RA remains a concern.Methods: Using the Swedish Biologics Register (ARTIS), the Swedish Cancer Register, pre-existing RA cohorts and cross-linkage with other national health and census registers, a national RA cohort (n  =  67 743) was assembled and patients who started anti-TNF therapy between 1998 and July 2006 (n  =  6604) were identified. A general population comparator (n  =  471 024) was also assembled and the incidence of lymphomas from 1999 to 31 December 2006 was assessed and compared in these individuals.Results: Among the 6604 anti-TNF-treated RA patients, 26 malignant lymphomas were observed during 26 981 person-years of follow-up, which corresponded to a relative risk (RR) of 1.35 (95% CI 0.82 to 2.11) versus anti-TNF-naive RA patients (336 lymphomas during 365 026 person-years) and 2.72 (95% CI 1.82 to 4.08) versus the general population comparator (1568 lymphomas during 3 355 849 person-years). RA patients starting anti-TNF therapy in 1998–2001 accounted for the entire increase in lymphoma risk versus the two comparators. By contrast, RR did not vary significantly by time since start of first treatment or with the accumulated duration of treatment, nor with the type of anti-TNF agent.Conclusion: Overall and as used in routine care against RA, TNF antagonists are not associated with any major further increase in the already elevated lymphoma occurrence in RA. Changes in the selection of patients for treatment may influence the observed risk.
  •  
10.
  • Askling, Johan, et al. (författare)
  • Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas : relative risks and time trends in the Swedish Biologics Register
  • 2009
  • Ingår i: Annals of the Rheumatic Diseases. - London, UK : BMJ. - 0003-4967 .- 1468-2060. ; 68:5, s. 648-653
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND:Tumour necrosis factor (TNF) antagonists have proved effective as treatment against rheumatoid arthritis (RA), but the unresolved issue of whether the use of anti-TNF therapy increases the already elevated risk of lymphoma in RA remains a concern.METHODS:Using the Swedish Biologics Register (ARTIS), the Swedish Cancer Register, pre-existing RA cohorts and cross-linkage with other national health and census registers, a national RA cohort (n = 67,743) was assembled and patients who started anti-TNF therapy between 1998 and July 2006 (n = 6604) were identified. A general population comparator (n = 471,024) was also assembled and the incidence of lymphomas from 1999 to 31 December 2006 was assessed and compared in these individuals.RESULTS:Among the 6604 anti-TNF-treated RA patients, 26 malignant lymphomas were observed during 26,981 person-years of follow-up, which corresponded to a relative risk (RR) of 1.35 (95% CI 0.82 to 2.11) versus anti-TNF-naive RA patients (336 lymphomas during 365,026 person-years) and 2.72 (95% CI 1.82 to 4.08) versus the general population comparator (1568 lymphomas during 3,355,849 person-years). RA patients starting anti-TNF therapy in 1998-2001 accounted for the entire increase in lymphoma risk versus the two comparators. By contrast, RR did not vary significantly by time since start of first treatment or with the accumulated duration of treatment, nor with the type of anti-TNF agent.CONCLUSION:Overall and as used in routine care against RA, TNF antagonists are not associated with any major further increase in the already elevated lymphoma occurrence in RA. Changes in the selection of patients for treatment may influence the observed risk.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 73
Typ av publikation
tidskriftsartikel (66)
doktorsavhandling (3)
bokkapitel (2)
konferensbidrag (1)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (68)
övrigt vetenskapligt/konstnärligt (4)
populärvet., debatt m.m. (1)
Författare/redaktör
Rantapää-Dahlqvist, ... (59)
Askling, Johan (11)
Geborek, Pierre (8)
Klareskog, Lars (8)
Dahlqvist, Solbritt ... (8)
Saxne, Tore (8)
visa fler...
Jacobsson, Lennart (8)
KLARESKOG, L (7)
Lindblad, S (7)
Lysholm, J (7)
Bertilsson, L (7)
Feltelius, N (7)
Baecklund, Eva (7)
Lindblad, Staffan (5)
Forsgren, Sture (5)
Brandt, L (5)
Feltelius, Nils (5)
Jönsen, Andreas (4)
Sturfelt, Gunnar (4)
Johansson, M (4)
Syvänen, Ann-Christi ... (4)
van Vollenhoven, Ron ... (4)
Arlestig, L. (4)
Geborek, P (4)
Saxne, T (4)
Bertilsson, Lennart (4)
Jacobsson, L. T. (4)
Rantapää-Dahlqvist, ... (4)
Baecklund, E (4)
Fored, C M (4)
Eriksson, C. (3)
Nilsson, Jan Åke (3)
Gunnarsson, Iva (3)
Waldenström, Anders (3)
Nordmark, Gunnel (3)
Johansson, Martin (3)
Rönnblom, Lars (3)
Wållberg Jonsson, So ... (3)
Boman, K. (3)
Hallmans, Göran (3)
Alfredsson, Lars (3)
Alenius, Gerd-Marie (3)
Jidell, Erik, 1955- (3)
van Vollenhoven, R (3)
Askling, J (3)
Fored, M (3)
Backlin, Carin (3)
Cöster, Lars (3)
Lysholm, Jörgen (3)
Fored, C. Michael (3)
visa färre...
Lärosäte
Umeå universitet (71)
Uppsala universitet (11)
Lunds universitet (9)
Karolinska Institutet (9)
Göteborgs universitet (2)
Språk
Engelska (70)
Svenska (3)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (24)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy